BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38001428)

  • 1. Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma.
    Liu ZT; Shen JT; Lei YJ; Huang YC; Zhao GQ; Zheng CH; Wang X; Wang YT; Chen L; Li ZX; Li SZ; Liao J; Yu TD
    BMC Cancer; 2023 Nov; 23(1):1141. PubMed ID: 38001428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma.
    Nguyen TT; Lee HS; Burt BM; Wu J; Zhang J; Amos CI; Cheng C
    Genome Med; 2022 Jan; 14(1):5. PubMed ID: 35016696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
    Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
    Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
    BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
    Yang Q; Zhu W; Gong H
    Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma.
    Li Q; Xie D; Yao L; Qiu H; You P; Deng J; Li C; Zhan W; Weng M; Wu S; Li F; Zhou Y; Zeng F; Zheng Y; Zhou H
    Front Immunol; 2022; 13():944378. PubMed ID: 36177001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
    Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
    Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 16. An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma.
    Han T; Liu Y; Wu J; Bai Y; Zhou J; Hu C; Zhang W; Guo J; Wang Q; Hu D
    Sci Rep; 2023 Mar; 13(1):5153. PubMed ID: 36991102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
    Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
    Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.